Clinical trial design in the era of precision medicine

Warner JL, Sethi TK, Rivera DR, Venepalli NK, Osterman TJ, Khaki AR, et al. Trends in FDA cancer registration trial design over time, 1969-2020. J Clin Oncol. 2020;38(15_suppl):2060.

Article  Google Scholar 

Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol. 1999;52(6):487–97.

CAS  PubMed  Article  Google Scholar 

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65.

CAS  PubMed  Article  Google Scholar 

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;38(1):1–10.

PubMed  PubMed Central  Article  Google Scholar 

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82.

CAS  PubMed  Article  Google Scholar 

Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65–74.

PubMed  Article  Google Scholar 

Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, et al. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst. 2015;107(11).

Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015;33(32):3817–25.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016;2(11):1452–9.

PubMed  Article  Google Scholar 

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25(5):744–50.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020;11(1):4965.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25(5):751–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

FDA. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication.

Wedam S, Fashoyin-Aje L, Bloomquist E, Tang S, Sridhara R, Goldberg KB, et al. FDA approval summary: palbociclib for male patients with metastatic breast cancer. Clin Cancer Res. 2020;26(6):1208.

CAS  PubMed  Article  Google Scholar 

Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. The master observational trial: a new class of master protocol to advance precision medicine. Cell. 2020;180(1):9–14.

CAS  PubMed  Article  Google Scholar 

Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. Snapshot: trial types in precision medicine. Cell. 2020;181(1):208 e1.

CAS  PubMed  Article  Google Scholar 

Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–77.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Li B, Shin H, Gulbekyan G, Pustovalova O, Nikolsky Y, Hope A, et al. Development of a drug-response modeling framework to identify cell line derived translational biomarkers that can predict treatment outcome to erlotinib or sorafenib. PLoS One. 2015;10(6):e0130700.

PubMed  PubMed Central  Article  CAS  Google Scholar 

van Gool AJ, Bietrix F, Caldenhoven E, Zatloukal K, Scherer A, Litton JE, et al. Bridging the translational innovation gap through good biomarker practice. Nat Rev Drug Discov. 2017;16(9):587–8.

PubMed  Article  CAS  Google Scholar 

Kraus VB. Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol. 2018;14(6):354–62.

CAS  PubMed  Article  Google Scholar 

Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Affairs (Project Hope). 2006;25(2):420–8.

Article  Google Scholar 

Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203–14.

CAS  PubMed  Article  Google Scholar 

Dhingra K. Oncology 2020: a drug development and approval paradigm. Ann Oncol. 2015;26(11):2347–50.

CAS  PubMed  Article  Google Scholar 

Van Norman GA. Drugs, Devices, and the FDA: Part 1: an overview of approval processes for drugs. JACC Basic Transl Sci. 2016;1(3):170–9.

PubMed  PubMed Central  Article  Google Scholar 

Gan HK, You B, Pond GR, Chen EX. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst. 2012;104(8):590–8.

PubMed  Article  Google Scholar 

Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483(7391):531–3.

CAS  PubMed  Article  Google Scholar 

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.

CAS  PubMed  Article  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.

CAS  PubMed  Article  Google Scholar 

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51.

CAS  PubMed  Article  Google Scholar 

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Reck M, Spira A, Besse B, Wolf J, Skoulidis F, Borghaei H, et al. MO01.32 CodeBreaK 200: a phase 3 multicenter study of sotorasib, a KRAS(G12C) Inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C Mutation. J Thorac Oncol. 2021;16(1):S29.

Article  Google Scholar 

Roberts C, Torgerson DJ. Understanding controlled trials: baseline imbalance in randomised controlled trials. BMJ. 1999;319(7203):185.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572.

PubMed  PubMed Central  Article  Google Scholar 

FDA. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and.

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay J-Y, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–36.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–9.

CAS  PubMed  Article 

留言 (0)

沒有登入
gif